Free Trial

Puma Biotechnology (PBYI) Earnings Date, Estimates & Call Transcripts

Puma Biotechnology logo
$2.75 -0.03 (-1.08%)
(As of 12/20/2024 05:31 PM ET)

Puma Biotechnology Latest Earnings Summary

Actual EPS
(Nov. 7)
$0.41 Beat By $0.10
Consensus EPS
(Nov. 7)
$0.31

Puma Biotechnology released Q3 2024 earnings on November 7, 2024, reporting an EPS of $0.41, which beat analysts' consensus estimates of $0.31 by $0.10. Quarterly revenue was reported to be $80.50 million, above analyst estimates of $71.32 million. With a trailing EPS of $0.48 and a P/E Ratio of 5.73, Puma Biotechnology's earnings are expected to grow 12.90% next year, from $0.31 to $0.35 per share.

Get Puma Biotechnology Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Puma Biotechnology and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

PBYI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PBYI Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Puma Biotechnology Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241-$0.22-$0.22-$0.22
Q2 20241$0.13$0.13$0.13
Q3 20241$0.09$0.09$0.09
Q4 20241$0.18$0.18$0.18
FY 20244$0.18$0.18$0.18
Q1 20251$0.01$0.01$0.01
Q2 20251$0.09$0.09$0.09
Q3 20251$0.08$0.08$0.08
Q4 20251$0.08$0.08$0.08
FY 20254$0.26$0.26$0.26
Q1 20261$0.10$0.10$0.10
Q3 20261$0.24$0.24$0.24

Puma Biotechnology Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/7/2024Q3 2024$0.31$0.41+$0.10$0.41$71.32M$80.50M
8/1/2024Q2 2024-$0.0970-$0.09+$0.0070-$0.09$43.99M$47.10M
5/2/2024Q1 2024-$0.22-$0.10+$0.12-$0.10$41.53M$43.80M
2/29/2024Q4 2023$0.33$0.26 -$0.07$0.26$73.22M$72.20M
11/2/2023Q3 2023$0.08$0.12+$0.04$0.12$57.30M$56.10M
8/3/2023Q2 2023$0.02$0.05+$0.03$0.05$51.37M$54.60M
5/4/2023Q1 2023-$0.10$0.03+$0.13$0.03$49.71M$52.80M
3/2/2023Q4 2022$0.06-$0.12 -$0.18-$0.12$57.10M$65.70M

Puma Biotechnology Earnings - Frequently Asked Questions

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earning data on Thursday, November 7, 2024. Learn more on PBYI's earnings history.

Puma Biotechnology updated its fourth quarter 2024 earnings guidance on Thursday, November, 7th. The company issued revenue guidance of $50.5 million-$55.0 million, compared to the consensus revenue estimate of $55.5 million.

In the previous quarter, Puma Biotechnology (NASDAQ:PBYI) reported $0.41 earnings per share (EPS) to beat the analysts' consensus estimate of $0.31 by $0.10. Learn more on analysts' earnings estimate vs. PBYI's actual earnings.

The conference call for Puma Biotechnology's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Puma Biotechnology's latest earnings report can be read online.
Read Transcript

Puma Biotechnology (NASDAQ:PBYI) has a recorded annual revenue of $243.57 million.

Puma Biotechnology (NASDAQ:PBYI) has a recorded net income of $21.59 million. PBYI has generated $0.48 earnings per share over the last four quarters.

Puma Biotechnology (NASDAQ:PBYI) has a trailing price-to-earnings ratio of 5.73 and a forward price-to-earnings ratio of 8.87.

Puma Biotechnology's earnings are expected to grow from $0.31 per share to $0.35 per share in the next year, which is a 12.90% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:PBYI) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners